239 related articles for article (PubMed ID: 19884907)
1. The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients.
Schenk PW; van Vliet M; Mathot RA; van Gelder T; Vulto AG; van Fessem MA; Verploegh-Van Rij S; Lindemans J; Bruijn JA; van Schaik RH
Pharmacogenomics J; 2010 Jun; 10(3):219-25. PubMed ID: 19884907
[TBL] [Abstract][Full Text] [Related]
2. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients.
Schenk PW; van Fessem MA; Verploegh-Van Rij S; Mathot RA; van Gelder T; Vulto AG; van Vliet M; Lindemans J; Bruijn JA; van Schaik RH
Mol Psychiatry; 2008 Jun; 13(6):597-605. PubMed ID: 17667959
[TBL] [Abstract][Full Text] [Related]
3. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
[TBL] [Abstract][Full Text] [Related]
4. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
[TBL] [Abstract][Full Text] [Related]
5. Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy.
Morinobu S; Tanaka T; Kawakatsu S; Totsuka S; Koyama E; Chiba K; Ishizaki T; Kubota T
Psychiatry Clin Neurosci; 1997 Aug; 51(4):253-7. PubMed ID: 9316174
[TBL] [Abstract][Full Text] [Related]
6. Relationship between age and tricyclic antidepressant plasma levels.
Nies A; Robinson DS; Friedman MJ; Green R; Cooper TB; Ravaris CL; Ives JO
Am J Psychiatry; 1977 Jul; 134(7):790-3. PubMed ID: 869057
[TBL] [Abstract][Full Text] [Related]
7. The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels.
Amsterdam J; Brunswick D; Mendels J
Am J Psychiatry; 1980 Jun; 137(6):653-62. PubMed ID: 6990798
[TBL] [Abstract][Full Text] [Related]
8. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
Hicks JK; Swen JJ; Thorn CF; Sangkuhl K; Kharasch ED; Ellingrod VL; Skaar TC; Müller DJ; Gaedigk A; Stingl JC;
Clin Pharmacol Ther; 2013 May; 93(5):402-8. PubMed ID: 23486447
[TBL] [Abstract][Full Text] [Related]
9. Plasma and erythrocyte levels of tricyclic antidepressants in depressed patients.
Linnoila M; Dorrity F; Jobson K
Am J Psychiatry; 1978 May; 135(5):557-61. PubMed ID: 347952
[TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations of tricyclic antidepressants in clinical practice.
Hollister LE
J Clin Psychiatry; 1982 Feb; 43(2):66-9. PubMed ID: 7056706
[TBL] [Abstract][Full Text] [Related]
11. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients.
Spina E; Pollicino AM; Avenoso A; Campo GM; Caputi AP
Int J Clin Pharmacol Res; 1993; 13(3):167-71. PubMed ID: 8225700
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of imipramine, desipramine and their 2- and 10-hydroxylated metabolites in human plasma and urine by high-performance liquid chromatography.
Chen AG; Wing YK; Chiu H; Lee S; Chen CN; Chan K
J Chromatogr B Biomed Sci Appl; 1997 May; 693(1):153-8. PubMed ID: 9200529
[TBL] [Abstract][Full Text] [Related]
13. Decreased plasma concentrations of imipramine and desipramine following cholestyramine intake in depressed patients.
Spina E; Avenoso A; Campo GM; Caputi AP; Perucca E
Ther Drug Monit; 1994 Aug; 16(4):432-4. PubMed ID: 7974637
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of tricyclic antidepressants and clinical efficacy: review of the literature -- part II.
Risch SC; Huey LY; Janowsky DS
J Clin Psychiatry; 1979 Feb; 40(2):58-69. PubMed ID: 581671
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels and antidepressive effect of imipramine.
Gram LF; Reisby N; Ibsen I; Nagy A; Dencker SJ; Bech P; Petersen GO; Christiansen J
Clin Pharmacol Ther; 1976 Mar; 19(3):318-24. PubMed ID: 770049
[TBL] [Abstract][Full Text] [Related]
16. Guidelines for therapeutic monitoring of tricyclic antidepressant plasma levels.
Orsulak PJ; Schildkraut JJ
Ther Drug Monit; 1979; 1(2):199-208. PubMed ID: 555572
[TBL] [Abstract][Full Text] [Related]
17. Patterns of plasma imipramine-desipramine concentrations in patients receiving concomitant fluphenazine decanoate.
Siris SG; Adan F; Lee A; Cooper TB; Mandeli J; Casey E
J Clin Psychiatry; 1988 Feb; 49(2):64-5. PubMed ID: 3338977
[TBL] [Abstract][Full Text] [Related]
18. [Tricyclic antidepressants (imipramine, desipramine, amitriptyline, nortriptyline)].
Yasuda K
Nihon Rinsho; 1995 Feb; 53 Su Pt 1():934-7. PubMed ID: 8753592
[No Abstract] [Full Text] [Related]
19. Tricyclic antidepressant plasma levels: the state of the art and clinical prospects.
Razavi D; Mendlewicz J
Neuropsychobiology; 1982; 8(2):73-85. PubMed ID: 7070646
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
